SEED Seed Innovations Limited

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

07 March 2024

SEED Innovations Limited

("SEED" or the "Company")

Transaction in Own Shares & TVR

SEED Innovations Ltd, the AIM-quoted company investment company providing shareholders with exposure to early-stage health, wellness and medical cannabis companies to which, in normal circumstances, they have limited access to, announces that it has purchased the following number of its shares of 1p each on the London Stock Exchange to be held in treasury (through Shard Capital Stockbrokers Limited ("Shard") acting as the Company's broker).

Following the purchase of these shares, the Company's issued ordinary share capital consists of 215,219,841 ordinary shares of which a total of 12,546,946 shares are held in treasury. The remaining 202,672,895 shares represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of the UK version of Regulation (EU) No. 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Shard on 07 March 2024 as part of the Programme as defined by the Company in the announcement on 29 September 2023.

Aggregate information: 

Individual transactions:

-Ends-

For further information on the Company please visit:  www.seedinnovations.co or contact: 

Notes

Seed Innovations Ltd

SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.